Cerevel Therapeutics (CERE) 10-Q2024 Q1 Quarterly report

Filed: 8 May 24, 4:17pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Avg

New words: AbbVie, advice, al, anesthesiologist, antitrust, AppTec, arm, auxiliary, Biden, binding, BIOSECURE, boost, bribe, captioned, category, certified, Children, Chinese, CJEU, climate, compensatory, compulsory, concealing, concept, coordinating, copy, covertly, CPRA, CTA, CTR, cyberattack, damage, defraud, degradation, Del, device, Dixon, DPF, draft, electrical, engineering, enjoin, ethical, experimental, falsifying, family, feet, forensic, framework, fulfillment, gathered, grantee, harder, Harlan, harmonized, Holdco, HTA, identification, impression, injunctive, intermediate, Ireland, Justice, kickback, knowingly, levodopa, longevity, main, merge, merged, MHRA, middle, mild, Northern, nurse, obfuscate, opposed, overtly, parking, penalty, pendency, plaintiff, Portability, portal, postponed, proportionality, prorated, proxy, qui, ransomware, reconciliation, referral, reframing, refund, released, relief, remuneration, renegotiate, rent, resurgence, retrospective, retrospectively, rolling, scheme, segment, Southern, space, square, streamline, Street, sublease, sued, surviving, Symphony, tam, teaching, telecommunication, territory, Topic, transmission, trick, troublesome, undetected, unfair, Unified, Unitary, UPC, waiting, whichever, whistleblower, willfully, WuXi, York

Removed: Addendum, altering, bill, bioresearch, Colorado, complicating, Connecticut, cycle, defer, derogation, detailed, dispositive, educational, enumerated, environmental, Equivalence, FDORA, IDTA, informed, intention, interactive, interpreting, largely, mitigating, predicted, preempted, recoverability, regime, resume, routine, safeguard, send, software, Test, uncured, Utah, version, Virginia

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

CERE similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Cerevel Therapeutics Holdings, Inc. (the “Company”) for the quarter ended March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: May 8, 2024	By:	/s/ Susan Altschuller
		Susan Altschuller, Ph.D.
		Chief Financial Officer (Principal Financial Officer)